Brand Reference: Arimidex
| Metric | Verified Benchmark | Source |
|---|---|---|
| Anastrozole RxNorm Concept ID | 84857 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0720 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $58.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $6.10 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $8.50 / mo | 21 Zero-PHI Verified Patient Logs |
Triazole competitive inhibitor of the cytochrome P450 CYP19A1 aromatase heme prosthetic group in adipose and peripheral tissues, blocking aromatization of androstenedione to estrone and testosterone to 17-beta-estradiol.
Across 21 community cost disclosures for Anastrozole (Arimidex), cash buyers routing around $58.00 retail markups capture a 89% discount ($6.10/mo benchmark vs $0.0720 NADAC acquisition).
Following administration (0.125 mg PO twice weekly (micro-dosed TRT adjunct)), Anastrozole achieves 83%–85% oral bioavailability and 24 hours ~70% aromatase suppression onset, governed by a 50 hours terminal half-life through hepatic n-dealkylation, hydroxylation (cyp3a4), and glucuronidation; <10% unchanged renal.
Before initiating Anastrozole at 0.125 mg PO twice weekly (micro-dosed TRT adjunct), clinical safety checklists rule out baseline estradiol < 18 pg/ml (osteopenia/endothelial crash risk); pregnancy. Logged tolerability patterns center on joint dryness if e2 over-suppressed (29% of reports), libido dip if over-dosed (18% of reports), hdl-c drop (11% of reports).
Across 21 verified cash-pay logs, Anastrozole achieves a 78.40% Worth-It rating with out-of-pocket spend averaging $8.50/mo versus $58.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 0.125 mg PO twice weekly (micro-dosed TRT adjunct) for Anastrozole; monthly out-of-pocket dropped to $5.37 compared with $58.00 retail.
Completed 10 weeks on Anastrozole (0.25 mg PO twice weekly). Zero notable side effects on steady dosing.
Consistent biomarker response on 1 mg PO daily (oncology) Anastrozole sourced via Compounding ($7.08/mo cash pay without insurance prior authorization).